HC Wainwright Issues Negative Estimate for KPTI Earnings

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) – HC Wainwright lowered their Q1 2025 earnings per share (EPS) estimates for Karyopharm Therapeutics in a research report issued on Wednesday, February 26th. HC Wainwright analyst E. White now anticipates that the company will post earnings of ($4.37) per share for the quarter, down from their previous forecast of ($4.35). HC Wainwright has a “Buy” rating and a $56.00 price objective on the stock. The consensus estimate for Karyopharm Therapeutics’ current full-year earnings is ($0.71) per share. HC Wainwright also issued estimates for Karyopharm Therapeutics’ Q2 2025 earnings at ($4.19) EPS, Q3 2025 earnings at ($3.39) EPS, Q4 2025 earnings at ($3.81) EPS, FY2025 earnings at ($15.63) EPS, FY2026 earnings at ($11.15) EPS and FY2027 earnings at ($9.05) EPS.

Karyopharm Therapeutics (NASDAQ:KPTI) last announced its quarterly earnings data on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The company had revenue of $30.54 million for the quarter, compared to the consensus estimate of $30.29 million.

A number of other research firms have also recently issued reports on KPTI. Robert W. Baird decreased their price objective on shares of Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating on the stock in a research report on Monday. StockNews.com cut shares of Karyopharm Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, November 22nd. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research report on Thursday, February 20th. Finally, Piper Sandler boosted their price target on shares of Karyopharm Therapeutics from $60.00 to $75.00 and gave the company an “overweight” rating in a research report on Wednesday, November 6th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat, Karyopharm Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $57.50.

Karyopharm Therapeutics Stock Performance

Shares of Karyopharm Therapeutics stock opened at $7.25 on Monday. Karyopharm Therapeutics has a 52-week low of $7.14 and a 52-week high of $25.50. The company’s 50 day moving average price is $9.81 and its 200-day moving average price is $11.24. The stock has a market capitalization of $61.05 million, a price-to-earnings ratio of -7.11 and a beta of 0.06.

Hedge Funds Weigh In On Karyopharm Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in KPTI. Velan Capital Investment Management LP purchased a new position in Karyopharm Therapeutics during the fourth quarter valued at $27,000. Focus Partners Wealth purchased a new stake in Karyopharm Therapeutics during the 4th quarter valued at about $31,000. TD Waterhouse Canada Inc. bought a new stake in Karyopharm Therapeutics during the 4th quarter valued at about $32,000. Two Sigma Advisers LP raised its holdings in Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock worth $52,000 after buying an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP bought a new position in shares of Karyopharm Therapeutics in the fourth quarter worth approximately $85,000. Institutional investors own 66.44% of the company’s stock.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).